Samsung Biologics and Kurma Partners announce collaboration for development and manufacturing of biologics
October 24, 2023Business Services Kurma Partners, Pharmacy, Samsung BioLogics
Samsung Biologics and Kurma Partners have announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ …
Roche announces acquisition of Telavant
October 23, 2023Business Services Gastrointestinal tract, Roche, Telavant
Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, a Roivant company, owned by …
AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC
October 23, 2023Research and Development AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology
AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the EU as a monotherapy for …
Genentech shares data from phase 3 trials of Vabysmo for retinal vein occlusion treatment
October 10, 2023Research and Development Genentech, Opthalmology, Vabysmo, phase 3 trial, retinal vein occlusion
Genentech has announced positive topline long-term results from its global phase 3 BALATON and COMINO trials which assessed extended treatment …
First patient dosed in Transgene and BioInvent’s phase 1 trial
October 10, 2023Research and Development BioInvent, Oncology, Transgene, oncology, phase 1 trial
Transgene and BioInvent have announced that the first patient has been treated in the phase 1 part B clinical trial …
BMS acquires Mirati Therapeutics for $4.8bn
October 9, 2023Business Services BMS, Mirati Therapeutics, Oncology, acquisition, bristol myers squibb, oncology
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a definitive agreement under which BMS …
GSK and Zhifei partner for shingles vaccine promotion in China
October 9, 2023Medical Communications GSK, Immunology, Shingrix, Vaccine, Zhifei, shingles
GSK has announced that it has come to an exclusive agreement with Chingqing Zhifei Biological Products to co-promote GSK’s shingles …
Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment
October 6, 2023Research and Development Nexviazyme, Pharmacy, Pompe disease, Sanofi
Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the treatment of Pompe disease at …
FDA accepts Sun Pharma’s NDA for deuruxolitinib
October 6, 2023Medical Communications Dermatology, FDA, NDA, SUun Pharma, deuruxolitinib
India-based pharma company Sun Pharmaceutical Industries has announced that the US Food and Drug Administration (FDA) has accepted its New …
FUJIFILM Diosynth Biotechnologies appoints Maja Pedersen as chief quality officer
October 6, 2023Business Services Fujifilm, Fujifilm Diosynth Biotechnologies, Maja Pedersen, Pharmacy, appointment, chief quality officer
CEO and president of FUJIFULM Diosynth Biotechnologies Lars Petersen has appointed Maja Pedersen as chief quality officer, where she will …
Janssen and Sanofi enter agreement for potential vaccine programme
October 5, 2023Business Services Immunology, Janssen, Sanofi, e coli, vaccines
Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with Sanofi for Janssen’s extraintestinal pathogenic …
Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine
October 5, 2023Research and Development COVID-19, Immunology, Moderna, clinical trial, influenza, vaccines
Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational combination vaccine against influenza and …
Sanofi and Teva partner for development of inflammatory bowel disease treatment
October 4, 2023Medical Communications Crohn’s disease, Gastrointestinal tract, Sanofi, Teva, bowel disease, ulcerative colitis
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation of TEV’574, a treatment for …
Eli Lilly to acquire POINT Biopharma
October 4, 2023Business Services Eli Lilly, Oncology, POINT Biopharma, acquisition, oncology
Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT to expand its pipeline of …
Acurx Pharmaceuticals announces positive data from phase 2b trial for C. difficile infection treatment
October 3, 2023Research and Development Acurx Pharmaceuticals, C. difficile, Infections and infestations, clinical trial, infection
Acurx Pharmaceuticals has announced that it has discontinued its phase 2b clinical trial of its lead antibiotic candidate, ibezapolstat, for …
WHO recommends new vaccine for prevention of malaria in children
October 3, 2023Medical Communications Immunology, Vaccine, WHO, malaria, malaria vaccine
The World Health Organization (WHO) has announced that it has recommended a new vaccine, R21/Matrix-M, for the prevention of malaria …
FDA grants marketing authorisation to DNA test for predisposition to certain cancers
October 2, 2023Research and Development FDA, Invitae, Oncology, cancer testing, oncology
The US Food and Drug Administration (FDA) has granted de novo marketing authorisation to the Invitae Common Hereditary Cancers Panel, …
Biogen’s biosimilar Tofidence approved by FDA
October 2, 2023Medical Communications Actemra, Biogen, FDA, Musculo-skeletal disorder, Tofidence
Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) as an intravenous formulation, a …
Austrian state secretary to speak at FlyPharma Europe 2023
September 29, 2023Business Services FlyPharma 2023, Vienna, flypharma
29 September 2023 — London, UK — FlyPharma Europe will welcome Mr Florian Tursky, the Austrian state secretary, to the …
Karuna Therapeutics submits NDA to FDA for schizophrenia treatment
September 29, 2023Medical Communications FDA, Karuna Therapeutics, Neurology, mental health, schizophrenia
Karuna Therapeutics has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration …
